Wuhan YZY Biopharma Co. Ltd. made its debut on the Hong Kong Stock Exchange, raising HK$121 million (US$15.48 million) in its IPO on Sept. 22, with shares (HKEX:02496) opening at the lower end of its range at HK$16 per share and ending the day at HK$16.60, a rise of 3.75%.
I-Mab Biopharma Co. Ltd. has regained full rights to its CD47 antibody program from Abbvie Inc., including lemzoparlimab, the most advanced candidate. The move, disclosed in a Sept. 22 U.S. SEC filing, eliminates the potential $1.295 billion in milestones associated with the amended collaboration deal signed in 2022.
Glycotope GmbH and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (Glycotargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.
Research at Kinnate Biopharma Inc. has led to the development of mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors reported to be useful for the treatment of cancer.
Aromatic ring-substituted methoxy derivatives have been described in a Shanghai Yingli Pharmaceutical Co. Ltd. patent as potentially useful for the treatment of liver and stomach cancer.
The cyclic imine toxins represent a growing family of neurotoxic lipophilic compounds made by a variety of benthic marine dinoflagellate species. These cause many shellfish food poisonings worldwide. Their cyclic nature confers exceptional chemical stability with bioaccumulation, but the inability to synthesize adequate amounts of these molecules has precluded basic research of their mechanisms of action.
Researchers from Technische Universität München and Universitätsklinikum Augsburg recently presented the discovery of novel radiohybrid-based minigastrin analogues.
Beactica Therapeutics AB has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS). The collaboration will focus on the translation of novel proteolysis-targeting degraders of TEAD under development by Beactica for treatment of cancer.
Sygnature Discovery Ltd. and Ube Corp. have established a collaboration on a hit-to-lead program to identify SHP2 degraders. The aim is to develop potent bifunctional compounds with excellent ADME and pharmacokinetic properties for efficient degradation of SHP2, a tyrosine-specific phosphatase implicated in human cancers.
Mitochondria regulate many processes that are altered in cancer cells, from metabolism to oxidative stress to apoptosis. The metabolic reprogramming in cancer cells promotes an immunosuppressive environment that drives cancer progression. However, in a recent study, researchers from the Salk Institute of Biological Sciences have identified succinate as a metabolite that accumulated due to specific disturbances in the mitochondrial electron transport chain.
RSS
